Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05TSJ
|
|||
| Former ID |
DNCL003510
|
|||
| Drug Name |
LY2784544
|
|||
| Synonyms |
LY2784544; 1229236-86-5; GANDOTINIB; LY 2784544; LY-2784544; Gandotinib (LY2784544); UNII-ANC71R916O; LY2784544(Gandotinib); ANC71R916O; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine; C23H25ClFN7O; 3-[(4-Chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(4-morpholinylmethyl)imidazo[1,2-b]pyridazin-6-amine; 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2], [3] | |
| Myeloproliferative neoplasm [ICD-11: 2A20; ICD-10: D47.7] | Phase 2 | [1], [2], [3] | ||
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25ClFN7O
|
|||
| Canonical SMILES |
CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F
|
|||
| InChI |
1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
|
|||
| InChIKey |
SQSZANZGUXWJEA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1229236-86-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
96068298, 104253503, 120478633, 124757625, 125164429, 135727468, 136348737, 136367592, 140870952, 141267114, 144116164, 152258431, 160647267, 160671532, 162011369, 162037797, 162202678, 163643258, 163908013, 164194019, 165248402, 172232458, 174006701, 174526788, 185971278, 198979005, 208265519, 224398200, 228617634, 240403281, 242060153, 243274225, 243709542, 249565592, 251963139, 252110133, 252220096, 252451565, 252543468, 252819783
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7909). | |||
| REF 2 | ClinicalTrials.gov (NCT01594723) A Study of LY2784544 in Participants With Myeloproliferative Neoplasms. U.S. National Institutes of Health. | |||
| REF 3 | LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway. Cancer Research 07/2011; 71(8 Supplement):2820-2820. | |||
| REF 4 | Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.